GlobalData : Sanofi's Dupixent likely to see label expansion to young eosinophilic esophagitis patients soon after approval in adults, says GlobalData - Marketscreener.com
4/6/2022 12:00:00 AM3 years 1 month ago
by MarketScreener
by MarketScreener
06 Apr 2022 Sanofi's Dupixent likely to see label expansion to young eosinophilic esophagitis patients soon after approval in adults, says GlobalData Posted in... | April 8, 2022
Following the news that Sanofi and Regeneron announced that the Food and Drug Administration (FDA) accepted a Priority Review of the supplemental Biologics License Application (sBLA) for Dupixent (du… [+1591 chars]
full article...